

## COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is in a Phase 2a trial. It is a broad-spectrum novel non-nucleoside replication inhibitor of the hepatitis C virus. Phase 1b studies in HCV-infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. CC-31244 is now in clinical trials as part of a cocktail for ultra-short therapy of 6 weeks. The Company's lead candidate for influenza is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs.

## RECENT NEWS

### **Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus**

Jan 22 2019, 8:00 AM EST

### **Cocrystal Announces Board Changes**

Jan 7 2019, 8:30 AM EST

### **Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck**

Jan 3 2019, 8:30 AM EST

## STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	79.3m
Last Price	\$2.65
52-Week Range	\$1.51 - \$6.45

02/21/2019 04:00 PM EST

## INVESTOR RELATIONS

Jenene Thomas Communications  
Jenene Thomas  
T: 833-475-8247  
[cocp@jtcir.com](mailto:cocp@jtcir.com)

## MANAGEMENT TEAM

### **Gary Wilcox, Ph.D.**

Chairman of the Board and Chief Executive Officer

### **Sam Lee, Ph.D.**

President

### **James J. Martin**

Chief Financial Officer

---

## COCRYSTAL PHARMA, INC.

19805 N. Creek Parkway  
Bothell, WA 98011  
US

---

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.